Outpatient blinatumomab with digital monitoring in patients with measurable residual disease positive (MRD plus ) B-ALL in a phase 4 study. Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Pardee, Timothy S.; Varela, Juan; Jeyakumar, Deepa; Keng, Michael Kenneth; Bar-Natan, Michal; Gundabolu, Krishna; Gayle, Arlene; McCann, Christopher; Xia, Qing; Ganzha, Sofia; Mergen, Noemi; Zaman, Faraz; Gordon, Paul R.; Khan, Sharif S.

Publication Date

  • June 1, 2024

webpage

published in

category

volume

  • 42

issue

  • 16